KKR-backed Karo completed the acquisition of the dermacosmetics branded business from Perrigo for €327m.

KKR-backed Karo, a European consumer healthcare company, completed the acquisition of the dermacosmetics branded business, including ACO, Biodermal, Emolium, and Iwostin, from Perrigo, a manufacturer of private label over-the-counter pharmaceuticals, for €327m. "We are pleased to announce the acquisition of Perrigo's Dermacosmetics business, home to trusted brands and high-quality products. We have been impressed by the talented team behind its success and the strong and loyal market reputation they've built. This acquisition aligns with KKR's strategy of investing in resilient, growth-oriented consumer health platforms. We look forward to working closely with the management team to accelerate growth by leveraging our global network, operational expertise, and long-term capital, unlocking lasting value in this dynamic and important sector," Inaki Cobo, KKR Partner.